S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Sienna Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:SNNA)

$0.16
-0.01 (-5.75 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$0.15
Now: $0.16
$0.18
50-Day Range
$0.11
MA: $0.41
$0.80
52-Week Range
$0.10
Now: $0.16
$12.97
Volume2.16 million shs
Average Volume1.45 million shs
Market Capitalization$5.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.67
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.27 per share

Profitability

Net Income$-73,470,000.00

Miscellaneous

Employees39
Market Cap$5.07 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.


Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) issued its earnings results on Thursday, August, 8th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.16. View Sienna Biopharmaceuticals' Earnings History.

When is Sienna Biopharmaceuticals' next earnings date?

Sienna Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Sienna Biopharmaceuticals.

What price target have analysts set for SNNA?

3 analysts have issued 12-month price targets for Sienna Biopharmaceuticals' stock. Their predictions range from $3.00 to $45.00. On average, they anticipate Sienna Biopharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 14,534.1% from the stock's current price. View Analyst Price Targets for Sienna Biopharmaceuticals.

What is the consensus analysts' recommendation for Sienna Biopharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sienna Biopharmaceuticals.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

Media headlines about SNNA stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sienna Biopharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Sienna Biopharmaceuticals.

Are investors shorting Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 86,300 shares, an increase of 39.6% from the August 30th total of 61,800 shares. Based on an average trading volume of 3,700,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the company's stock are sold short. View Sienna Biopharmaceuticals' Current Options Chain.

Who are some of Sienna Biopharmaceuticals' key competitors?

What other stocks do shareholders of Sienna Biopharmaceuticals own?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)
  • Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Alexander Azoy, CFO & Controller (Age 43)
  • Mr. Majed Kheir, VP of Operations (Age 41)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $0.16.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $5.07 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 39 workers across the globe.View Additional Information About Sienna Biopharmaceuticals.

What is Sienna Biopharmaceuticals' official website?

The official website for Sienna Biopharmaceuticals is http://www.siennabio.com/.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  587
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel